NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

You presume just because you know the general details of a contract you can understand everything.

The general terms of their contracts are outlined in their financials. It doesn’t mean you’ll understand or know everything about them.

We have yet to receive their annual report for 2023, but we do know the company has funded development. We also know they cannot market. We do not know how much substantial revenue or when if any, it has come in on the specials program.

We do know that Sawston is the means and Advent is the service provider in the UK. This makes sense since NWBO itself doesn’t do manufacturing, it contracts that service out.

The space leased is not the same it’s the services provided nor the infrastructure built for Advent to provide the services. Advent is under contract. Advent is required to provide the services to NWBO when there is demand, and the requirement under the regional development contract to help other companies would be a cost to NWBO, not revenue. But it does help subsidize the building, staffing and maintaining if a GMP facility to manufacture DCVax-L at reasonably low cost to NWBO and it is a small portion of the ultimately available space.

Effectively, it isolates what would be a serious COST center off of the balance sheet with set costs that are more manageable and that can be symbiotically subsidized, for now, and that facility s the germ seed for the larger facility that will likely use different technology and be automated. It is a perfect launch pad and allows manufacturing to be scaled as needed, which for this are, in biotech, is extremely innovative.